Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
But now it must show that varseta-M can move into a registrational trial.
New data with pasritamig plus docetaxel support a recent pivotal start.
